Treatment of kidney allograft with chronic antibody-mediated rejection using tocillizmab .

The treatment of kidney allograft with a chronic antibody-mediated rejection using anti-IL-6 receptor antibody (tocillizmab) - Treatment of chronic antibody-mediated rejection with tocillizmab .

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs031180443

Enrollment

Registered

2019-03-28

Start date

2018-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic antibody-mediated rejection kidney transplantation, chronic antibody-mediated rejection

Interventions

The treatment of CAMR of kidney allograft with tocillizmab.

chronic antibody-mediated rejection, kidney transplantation

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. A patient with biopsy-proven chronic antibody-mediated rejection (CAMR) with positive donor-specific anti-HLA antibodies. 2. A patient which was resistant to the standard care of treatment for CAMR. 3. eGFR of patients > 30ml/min/1.73m2 4. A patient who willing to attend this study.

Exclusion criteria

Exclusion criteria: 1. A patient with severe infection 2. A patient with active tuberculosis 3. A patient with malignancy 4. A patient having allergy to tocillizumab 5. A patient with severe complication which may affect the outcome of this study. 6. A patient with pregnancy

Design outcomes

Primary

Measure	Time frame
The improvement of allograft function 1 year after the treatment	—

Secondary

Measure	Time frame
The long-term graft outcome after the treatment	—

Contacts

Public ContactKAZUNOBU SHINODA

Toho University, Faculty of Medicine

shishido@med.toho-u.ac.jp+81-3-5763-6648

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026